News | Breast Imaging | August 26, 2015

Kubtec Patent Promotes Strong Prognosis for the Future of Breast Conserving Surgery

Improving surgical outcomes for early stage breast cancer patients

breast imaging

Kubtec announced the U.S. Patent & Trademark Office has issued Patent No. 14/503,130 for the technology incorporated into the Mozart System with TomoSpec Technology. This patent recognizes that the Mozart System with TomoSpec Technology, the world’s first portable 3-D Digital Specimen Tomosynthesis Imaging System, is unique in its field.

The Mozart System with TomoSpec Technology allows surgeons to bring 3-D tomosynthesis imaging directly into the Operating Room for lumpectomy and partial mastectomy procedures. It gives surgical teams the ability to make faster and more precise intraoperative determinations of the successful excision of tumor margins. Prior to the Mozart System with TomoSpec Technology, surgeons were restricted to less effective modes of multiple 2-D imaging, or waiting while a specimen was transported from the operating room to another location for 3-D analysis.   

“Surgeons often do not have the time to wait for off-site 3-D image analysis.  A result of this is that around 25 percent of lumpectomy patients will require a second procedure1, as follow up analysis frequently indicates that the tumor has not been completely excised during surgery,” said Vikram Butani, president and CEO of Kubtec. “Our goal is to reduce that number by giving surgeons and radiologists the most advanced digital specimen radiography tools that enable them to precisely identify tumor margins during the operation itself. This shortens procedure times and decreases the risk that a re-excision will be necessary. That’s better for the patient and it reduces hospital costs, too.”

Chester Lowe, Ph.D.  director of research and development at Kubtec, commented, “This patent confirms how unique and important the technologies integrated into the design of the Mozart Digital Specimen Tomosynthesis Imaging System really are. We believe that the Mozart System with TomoSpec Technology will have a major impact on breast cancer procedures and drive positive outcomes for patients.”

For more information:

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init